Polaris Group is conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.
